Related Experiment Video
Updated: Jul 13, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models
Xiaoming Xie1, Weiya Xia, Zhongkui Li
1Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Abstract:
Pancreatic cancer is an aggressive malignancy with morbidity rates almost equal to mortality rates because of the current lack of effective treatment options. Here, we describe a targeted approach to treating pancreatic cancer with effective therapeutic efficacy and safety in noninvasive imaging models. We developed a versatile expression vector "VISA" (VP16-GAL4-WPRE integrated systemic amplifier) and a CCKAR (cholecystokinin type A receptor) gene-based, pancreatic-cancer-specific promoter VISA (CCKAR-VISA) composite to target transgene expression in pancreatic tumors in vivo. Targeted expression of BikDD, a potent proapoptotic gene driven by CCKAR-VISA, exhibited significant antitumor effects on pancreatic cancer and prolonged survival in multiple xenograft and syngeneic orthotopic mouse models of pancreatic tumors with virtually no toxicity.
Insights
Researchers developed a novel gene therapy targeting pancreatic cancer using a specific promoter and a proapoptotic gene. This approach demonstrated significant antitumor effects and improved survival in mouse models with minimal toxicity.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Pancreatic cancer is a highly aggressive malignancy with poor prognosis due to limited effective treatments.
- Current therapeutic strategies for pancreatic cancer often lack efficacy and exhibit significant toxicity.
- There is a critical need for novel, targeted treatment approaches to improve patient outcomes.
Purpose of the Study:
- To develop and evaluate a targeted gene therapy strategy for pancreatic cancer.
- To assess the therapeutic efficacy and safety of a novel gene delivery system in preclinical pancreatic cancer models.
- To investigate the potential of a pancreatic cancer-specific promoter to drive therapeutic gene expression.
Main Methods:
- Development of a versatile expression vector (VISA) and a pancreatic cancer-specific promoter (CCKAR-VISA).
- Targeted delivery of a proapoptotic gene (BikDD) using the CCKAR-VISA system in vivo.
- Evaluation of antitumor effects and survival in xenograft and syngeneic orthotopic mouse models of pancreatic cancer.
- Assessment of therapeutic safety and toxicity in preclinical models.
Main Results:
- The CCKAR-VISA system successfully targeted transgene expression to pancreatic tumors.
- Targeted expression of BikDD demonstrated significant antitumor activity against pancreatic cancer.
- The gene therapy approach prolonged survival in multiple preclinical models.
- The treatment exhibited virtually no observable toxicity in the tested models.
Conclusions:
- A novel targeted gene therapy approach using CCKAR-VISA and BikDD shows significant therapeutic potential for pancreatic cancer.
- This strategy offers effective antitumor efficacy and a favorable safety profile in preclinical models.
- The findings support further investigation of this targeted gene therapy for clinical application in pancreatic cancer treatment.
